307 related articles for article (PubMed ID: 24947099)
21. Histopathologic and Clinical Characterization of Thyroid Tumors Carrying the BRAF(K601E) Mutation.
Afkhami M; Karunamurthy A; Chiosea S; Nikiforova MN; Seethala R; Nikiforov YE; Coyne C
Thyroid; 2016 Feb; 26(2):242-7. PubMed ID: 26422023
[TBL] [Abstract][Full Text] [Related]
22. Can the microRNA signature distinguish between thyroid tumors of uncertain malignant potential and other well-differentiated tumors of the thyroid gland?
Lassalle S; Hofman V; Ilie M; Bonnetaud C; Puisségur MP; Brest P; Loubatier C; Guevara N; Bordone O; Cardinaud B; Lebrigand K; Rios G; Santini J; Franc B; Mari B; Al Ghuzlan A; Vielh P; Barbry P; Hofman P
Endocr Relat Cancer; 2011 Oct; 18(5):579-94. PubMed ID: 21778212
[TBL] [Abstract][Full Text] [Related]
23. Morphological parameters able to predict BRAF(V600E) -mutated malignancies on thyroid fine-needle aspiration cytology: Our institutional experience.
Rossi ED; Bizzarro T; Martini M; Capodimonti S; Fadda G; Larocca LM; Schmitt F
Cancer Cytopathol; 2014 Dec; 122(12):883-91. PubMed ID: 25156883
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma.
Nakamura N; Erickson LA; Jin L; Kajita S; Zhang H; Qian X; Rumilla K; Lloyd RV
Endocr Pathol; 2006; 17(3):213-23. PubMed ID: 17308358
[TBL] [Abstract][Full Text] [Related]
25. HBME-1 expression in follicular tumor of the thyroid: an investigation of whether it can be used as a marker to diagnose follicular carcinoma.
Ito Y; Yoshida H; Tomoda C; Miya A; Kobayashi K; Matsuzuka F; Kakudo K; Kuma K; Miyauchi A
Anticancer Res; 2005; 25(1A):179-82. PubMed ID: 15816536
[TBL] [Abstract][Full Text] [Related]
26. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.
Capper D; Preusser M; Habel A; Sahm F; Ackermann U; Schindler G; Pusch S; Mechtersheimer G; Zentgraf H; von Deimling A
Acta Neuropathol; 2011 Jul; 122(1):11-9. PubMed ID: 21638088
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules.
Park YJ; Kwak SH; Kim DC; Kim H; Choe G; Park DJ; Jang HC; Park SH; Cho BY; Park SY
J Korean Med Sci; 2007 Aug; 22(4):621-8. PubMed ID: 17728499
[TBL] [Abstract][Full Text] [Related]
28. Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions.
Mataraci EA; Ozgüven BY; Kabukçuoglu F
Pol J Pathol; 2012 Mar; 63(1):58-64. PubMed ID: 22535608
[TBL] [Abstract][Full Text] [Related]
29. Combined immunohistochemistry for thyroid peroxidase, galectin-3, CK19 and HBME-1 in differential diagnosis of thyroid tumors.
Paunovic I; Isic T; Havelka M; Tatic S; Cvejic D; Savin S
APMIS; 2012 May; 120(5):368-79. PubMed ID: 22515291
[TBL] [Abstract][Full Text] [Related]
30. Is BECLIN-1 Immunoreactivity More Effective than HBME-1 in Diagnosis of Papillary Thyroid Cancer?
Yeşil C; Kandemir O; Haksever H; Dabakoğlu T
Acta Chir Belg; 2015; 115(4):299-305. PubMed ID: 26324033
[TBL] [Abstract][Full Text] [Related]
31. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid.
Rossi ED; Raffaelli M; Mule' A; Miraglia A; Lombardi CP; Vecchio FM; Fadda G
Histopathology; 2006 Jun; 48(7):795-800. PubMed ID: 16722927
[TBL] [Abstract][Full Text] [Related]
32. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
[TBL] [Abstract][Full Text] [Related]
33. BRAF mutation detection in indeterminate thyroid cytology specimens: underlying cytologic, molecular, and pathologic characteristics of papillary thyroid carcinoma.
Ohori NP; Singhal R; Nikiforova MN; Yip L; Schoedel KE; Coyne C; McCoy KL; LeBeau SO; Hodak SP; Carty SE; Nikiforov YE
Cancer Cytopathol; 2013 Apr; 121(4):197-205. PubMed ID: 22887810
[TBL] [Abstract][Full Text] [Related]
34. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
35. Differential diagnostic significance of HBME-1, CK19 and S100 in various thyroid lesions.
Palo S; Biligi DS
Malays J Pathol; 2017 Apr; 39(1):55-67. PubMed ID: 28413206
[TBL] [Abstract][Full Text] [Related]
36. [Expression of Twist in papillary thyroid carcinomas and its roles in differential diagnosis].
He CN; He L; Cheng JQ; Chen SC; Zhao HF; Zhai JP; Zhang J
Zhonghua Bing Li Xue Za Zhi; 2008 Jan; 37(1):35-9. PubMed ID: 18509983
[TBL] [Abstract][Full Text] [Related]
37. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin.
Ceyran AB; Şenol S; Şimşek BÇ; Sağıroğlu J; Aydın A
Int J Clin Exp Pathol; 2015; 8(4):3670-80. PubMed ID: 26097548
[TBL] [Abstract][Full Text] [Related]
38. Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns.
Eszlinger M; Paschke R
Mol Cell Endocrinol; 2010 Jun; 322(1-2):29-37. PubMed ID: 20083161
[TBL] [Abstract][Full Text] [Related]
39. Ultrasound Risk Assessment Combined with Molecular Markers of Galectin-3, c-MET, HBME-1 and CK19 for Diagnosis of Malignant and Benign Thyroid Nodules.
Han RL; Wang J; Zhang FJ; Zhao N; Gao BL
Pathol Oncol Res; 2019 Jul; 25(3):1075-1081. PubMed ID: 30361909
[TBL] [Abstract][Full Text] [Related]
40. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma.
Kim TY; Kim WB; Song JY; Rhee YS; Gong G; Cho YM; Kim SY; Kim SC; Hong SJ; Shong YK
Clin Endocrinol (Oxf); 2005 Nov; 63(5):588-93. PubMed ID: 16268813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
